Activation of IgG antibody and mucosal T cell responses to MERS-CoV in human nasopharynx-associated lymphoid tissue by a ChAdOx1 vectored vaccine candidate and inactivated MERS-CoV
6 affiliations
- 1Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
- 2Department of Medical Virology, Vector-Borne Diseases Laboratories, Public Health Authority, Jazan, Saudi Arabia
- 3ENT Departments, Alder Hey Children’s Hospital, Liverpool, UK
- 4ENT Departments, Aintree University Hospital, Liverpool, UK
- 5Jenner Vaccine Institute; Oxford Vaccine Group; Pandemic Sciences Institute; CAMS Oxford Institute, University of Oxford ; Chinese Academy of Medical Sciences & Peking Union Medical College, Oxford, UK
- 6Section of Immunology, Department of Microbes, Infection and Immunity, University of Surrey, Surrey, UK
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) causes serious infection in humans with up to 40% mortality. As MERS-CoV infects humans via nasopharyngeal mucosa, local mucosal immunization may provide an effective vaccination strategy. Nasopharynx-associated lymphoid tissues (NALT, comprising adenotonsillar tissues) are immune induction sites for intranasal vaccines. We studied the capacity of a viral vectored MERS candidate vaccine (ChAdOx1 MERS) and inactivated MERS-CoV in activating cellular and antibody responses in the NALT. Mononuclear cells isolated from adenotonsillar tissues from children and adults were stimulated with ChAdOx1 MERS and heat- or radiation-inactivated MERS-CoV, followed by analysis of anti-MERS IgG antibody and cytokines (IFNγ and TNFα) in cell culture supernatants by ELISA. CD4+ and CD8+ T cell responses, including proliferation and expression of cytokines and cytotoxic molecules were evaluated by flow cytometry. ChAdOx1 MERS induced marked spike-specific anti-MERS IgG antibody responses, which were significantly stronger than those induced by inactivated MERS-CoV. ChAdOx1 MERS also activated higher CD4+ and CD8+ T cell proliferative responses, cytokine expression (IFNγ, TNFα) by CD4+ T cells and cytotoxic perforin and granzyme B expression by CD8+ T cells than by inactivated MERS-CoV. Both antibody and T cell responses were shown stronger in adults than in children. There was a positive correlation between CD4+ T cell proliferation and the antibody response. Human NALT offers an efficient immune induction site for Spike-specific anti-MERS antibody and T cell response. Viral vectored ChAdOx1 MERS induces marked antibody and T cell responses in the NALT, supporting its potential as a mucosal (e.g. intranasal) vaccine against MERS.
Related
- AMnESTI Reverses Age-Associated Lung Immune Decline to Drive Heterosubtypic Protection by Inactivated Influenza Vaccines
- Ex vivo IL-1β, IL-6, TNF-α, and IL-8 responses 2 years after critical COVID-19 are associated with age and innate immune activation
- Study on the clinical outcomes of COVID-19 infection and immune responses following the third booster dose of inactivated COVID-19 vaccine in hematologic disease patients
- A Unique Case of Odontoid Metastasis Reveals Nasopharynx Carcinoma: Case Management With the Posterolateral Epidural Supra-C2-Root Approach (PESCA) Technique in Open Surgery
- Presence of Dolosigranulum pigrum in the nasopharynx and its relationship with respiratory health status in paediatric population
BibTeX
@article{shrwani2026activation,
title = {{Activation of IgG antibody and mucosal T cell responses to MERS-CoV in human nasopharynx-associated lymphoid tissue by a ChAdOx1 vectored vaccine candidate and inactivated MERS-CoV}},
author = {Khalid J. Shrwani and Ravi Sharma and Madhankumar Krishnan and Samuel Leong and Teresa Lambe and Sarah C. Gilbert and Nigel Cunliffe and Qibo Zhang},
journal = {Human Vaccines \& Immunotherapeutics},
year = {2026},
month = nov,
doi = {10.1080/21645515.2026.2756059},
url = {https://doi.org/10.1080/21645515.2026.2756059},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Activation of IgG antibody and mucosal T cell responses to MERS-CoV in human nasopharynx-associated lymphoid tissue by a ChAdOx1 vectored vaccine candidate and inactivated MERS-CoV
AU - Khalid J. Shrwani
AU - Ravi Sharma
AU - Madhankumar Krishnan
AU - Samuel Leong
AU - Teresa Lambe
AU - Sarah C. Gilbert
AU - Nigel Cunliffe
AU - Qibo Zhang
PY - 2026
DA - 2026/11/09
JO - Human Vaccines & Immunotherapeutics
DO - 10.1080/21645515.2026.2756059
UR - https://doi.org/10.1080/21645515.2026.2756059
AB - Middle East respiratory syndrome coronavirus (MERS-CoV) causes serious infection in humans with up to 40% mortality. As MERS-CoV infects humans via nasopharyngeal mucosa, local mucosal immunization may provide an effective vaccination strategy. Nasopharynx-associated lymphoid tissues (NALT, comprising adenotonsillar tissues) are immune induction sites for intranasal vaccines. We studied the capacity of a viral vectored MERS candidate vaccine (ChAdOx1 MERS) and inactivated MERS-CoV in activating cellular and antibody responses in the NALT. Mononuclear cells isolated from adenotonsillar tissues from children and adults were stimulated with ChAdOx1 MERS and heat- or radiation-inactivated MERS-CoV, followed by analysis of anti-MERS IgG antibody and cytokines (IFNγ and TNFα) in cell culture supernatants by ELISA. CD4+ and CD8+ T cell responses, including proliferation and expression of cytokines and cytotoxic molecules were evaluated by flow cytometry. ChAdOx1 MERS induced marked spike-specific anti-MERS IgG antibody responses, which were significantly stronger than those induced by inactivated MERS-CoV. ChAdOx1 MERS also activated higher CD4+ and CD8+ T cell proliferative responses, cytokine expression (IFNγ, TNFα) by CD4+ T cells and cytotoxic perforin and granzyme B expression by CD8+ T cells than by inactivated MERS-CoV. Both antibody and T cell responses were shown stronger in adults than in children. There was a positive correlation between CD4+ T cell proliferation and the antibody response. Human NALT offers an efficient immune induction site for Spike-specific anti-MERS antibody and T cell response. Viral vectored ChAdOx1 MERS induces marked antibody and T cell responses in the NALT, supporting its potential as a mucosal (e.g. intranasal) vaccine against MERS.
SN - 2164-5515
SN - 2164-554X
ER -